Publications Over the Past 5 Years of Grant Funding By CRC Principle Investigators

Publications Over the Past 5 Years of Grant Funding By CRC Principle Investigators (in bold). For additional information regarding these or any other publication please consult the National Library of Medicine's PubMed

1. Zapata, J.M., Krajewska, M, Morse, H.C.III, Choi, Y., and Reed, J.C.TRAF-domain and Bcl-2 cooperate to induce small B-cell lymphoma/Chronic lymphocytic leukemia in transgenic mice. (2004) Submitted

2. Zapata, J.M., Pedersen, I.M., Hrajewska, M., Thomas, M., and Reed, J.C. 2002. Transgenic mouse models of low grade B-cell lymphoma. Podium Presentation. Blood (abstract 751, page 200a)

3. Zapata, J.M., Pedersen, I.M., Krajewska, M., and Reed, J.C. TRAF2 and Bcl-2 cooperate to develop small B-cell lymphoma/chronic lymphocytic leukemia in mice. Podium presentation. X international workshop on CLL. 2003. Leukemia Lymphoma 44, (2), abstract 32

4. S Kitada and JC Reed, MCL1 promoter insertions dial-up aggressiveness of chronic leukemia---Editorials. JNCI Vol 96 No. 9, May 5, 2004

5. Becattini B, Kitada S, Leone M, Monosov E, Chandler S , Zhai D, Kipps TJ, Reed JC, Pellecchia M: Rational design and real time in-cell detection of the pro-apoptotic activity of a novel compound targeting Bcl-XL. Chemistry & Biology Vol 11: 389-396, March 2004

6. Leone M. Zhai D. Sareth S. Kitada S. Reed JC. Pellecchia M. Cancer prevention by tea polyphenols is linked to their direct inhibition of antiapoptotic Bcl-2-family proteins. Cancer Research. 63(23):8118-21, 2003 December 1.

7. Kitada S. Leone M. Sareth S. Zhai D. Reed JC. Pellecchia M. Discovery, characterization, and structure-activity relationships studies of proapoptotic polyphenols targeting B-cell lymphocyte/leukemia-2 proteins. [Journal Article] Journal of Medicinal Chemistry. 46(20):4259-64, 2003 September 25.

8. Bannerji R±. Kitada S±. Flinn IW. Pearson M. Young D. Reed JC. Byrd JC. Apoptotic-regulatory and complement-protecting protein expression in chronic lymphocytic leukemia: relationship to in vivo rituximab resistance. [Journal Article] Journal of Clinical Oncology. 21(8):1466-71, 2003 Apr 15.

9. Eksioglu-Demiralp E. Kitada S. Carson D. Garland J. Andreef M. Reed JC. A method for functional evaluation of caspase activation pathways in intact lymphoid cells using electroporation-mediated protein delivery and flow cytometric analysis. [Journal Article] Journal of Immunological Methods. 275(1-2):41-56, 2003 Apr 1.

10. Aron JL. Parthun MR. Marcucci G. Kitada S. Mone AP. Davis ME. Shen T. Murphy T. Wickham J. Kanakry C. Lucas DM. Reed JC. Grever MR. Byrd JC. Depsipeptide (FR901228) induces histone acetylation and inhibition of histone deacetylase in chronic lymphocytic leukemia cells concurrent with activation of caspase 8-mediated apoptosis and down-regulation of c-FLIP protein. [Journal Article] Blood. 102(2):652-8, 2003 Jul 15.

11. Kitada S. Pedersen IM. Schimmer AD. Reed JC. Dysregulation of apoptosis genes in hematopoietic malignancies. [Review] [150 refs] [Journal Article. Review., Academic] Oncogene. 21(21):3459-74, 2002 May 13.

12. Kitada S, Young D, Pearson M, Flinn IW, Shinn CA, Reed JC, Byrd JC. Mcl-1/Bax ratio is a predictor for outcome of Rituximab therapy in patients with CLL. ASH Abstract 2002.

13. Byrd JC. Kitada S. Flinn IW. Aron JL. Pearson M. Lucas D. Reed JC. The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction. [Clinical Trial. Journal Article. Multicenter Study] Blood. 99(3):1038-43, 2002 Feb 1.

14. Chu P. Deforce D. Pedersen IM. Kim Y. Kitada S. Reed JC. Kipps TJ. Latent sensitivity to Fas-mediated apoptosis after CD40 ligation may explain activity of CD154 gene therapy in chronic lymphocytic leukemia. Proceedings of the National Academy of Sciences of the United States of America. 99(6):3854-9, 2002 Mar 19.

15. Reed JC. Kitada S. Kim Y. Byrd J. Modulating apoptosis pathways in low-grade B-cell malignancies using biological response modifiers. Seminars in Oncology. 29(1 Suppl 2):10-24, 2002

16. Suh W-S, Kim YS, Schimmer A, Kitada S, Andreeff M, Sporn M, Suh N and Reed JC, Triterpenoids CDDO and CDDOm down-regulate FLIP expression and sensitize AML cells to trail-induced apoptosis. ASH Abstract 2001

17. Zelphati O. Wang Y. Kitada S. Reed JC. Felgner PL. Corbeil J. Intracellular delivery of proteins with a new lipid-mediated delivery system. Journal of Biological Chemistry. 276(37):35103-10, 2001.

18. Zapata JM, Krajewska M, Krajewski S, Kitada S, Welsh K, Monks A, McCloskey N, Gordon J, Kipps TJ, Gascoyne RD, Shabaik A, Reed JC. TNFR-Associated Factor family protein expression in normal tissues and lymphoid malignancies. J Immunol 165: 5084-5096, 2000.

19. Kitada S., Zapata JM, Andreeff M, Reed JC. Protein kinase inhibitors flavopiridol and 7-hydroxy-staurosporine down-regulate antiapoptosis proteins in B-cell chronic lymphocytic leukemia. Blood 96: 393-397, 2000.

20. Kitada S, Pearson M, Flinn IW, Shinn CA, Reed JC, and Byrd JC. In vivo clearance of CLL cells by Rituximab involves apoptosis by a caspase 9 pathway. ASH Abstract 2000.

21. Schimmer AD., Walsh K., Pinilla C., Bonneau M., Wang Z., Krajewska M., Bonneau M., Pedersen IM., Kitada S., Scott FL., Bailly-Maitre B., Glinsky G., Scudiero D., Sausville E., Salvesen G., Nefzi A., Ostresh JM., Houghten RA., and Reed JC., Small-molecule antagonists of apoptosis-suppressor XIAP exhibit broad anti-tumor activity, Cancer Cell, 2004, 5:25-35.

22. Schimmer AD., Pedersen IM., Minden MD., Reed JC., Bcl-2 and Apoptosis in Chronic Lymphocytic Leukemia, Curr. Treat. Options Oncol., 2003, 4:211-8.

23. Schimmer A, Pedersen IM , Kitada S, Eksioglu-Demiralp E, Minden MD, Pinto R, Mah K, Andreeff M, Kim, Youngsoo; Suh, Won Suk and Reed JC. Functional blocks in Caspase activation pathways are common in leukemia and predict patient-response to induction chemotherapy, Cancer Research, 2003, 63:1242-8

24. Reed JC., Kitada S., Pedersen IM., Shimmer A., Dysregulation of apoptosis genes in hematopoietic malignancies. Oncogene, 2002, 21:3459-74

25. Pedersen IM, Kitada S, Leoni LM, Zapata JM, Karres J, Tsukada N, Kipps TJ, Choi YS, Bennet F Reed JC. Protection of CLL B-cells by a follicular dendritic cell line is dependent on induction of Mcl-1. Blood, 2002, 100:1795-801.

26. Pedersen IM, Kitada S, Schimmer A, Kim Y, Zapata JM, Charboneau L, Rassenti L, Andreeff M, Bennett F, Sporn MB, Liotta LD, Kipps TJ, Reed JC. The triterpenoid CDDO induces apoptosis in refractory CLL B cells. Blood 2002 100:2965-2972

27. Anissa Agadir, Shinichi Kitada, Jian Gu, Barbara Becattini, Marilisa Leone, Sina Sareth, Maurizio Pellecchia, Juan M. Zapata, Thomas J. Kipps, John C. Reed. The BD CBA Human Apoptosis Assay: A Novel Tool for Monitoring Changes in Bcl-2, Active Caspase-3, and Cleaved PARP in Patients with CLL. Acknowledgement: Special thanks to Dr. Rassenti, Ph.D., CRC Tissue Core Director, for providing CLL samples. ASH Abstract 2003

28. Irene M. Pedersen, Juan Zapata, Temesgen Samuel, Fiona Scott, Michael Sporn, Thomas J. Kipps, Guy Salvesen, John C. Reed. The Triterpenoid CDDO-Imidazolide Induces Apoptosis of CLL B-Cells, through a Bcl-2-Independent Mechanism and Synergizes with Fludarabine ASH Abstract 2003

29. Shinichi Kitada, Barbara Becattini, Marilisa Leone, Edward Monosov, Sharon Chandler, Thomas J. Kipps, John C. Reed, Maurizio Pellecchia. Rational Design and Real Time In-Cell Detection of the Pro-Apoptotic Activity of a Novel Compound Targeting Bcl-2/Bcl-XL. Acknowledgement: Special thanks to Dr. Rassenti, Ph.D., CRC Tissue Core Director, for providing CLL samples. ASH Abstract 2003

30. Massimo Mangiola, Shinichi Kitada, Irene M. Pedersen, Clemencia Pinilla, Thomas J. Kipps, John C. Reed. XIAP Antagonist-Induced Cell Death in B-Cell Isolated from Patients with Chronic Lymphocytic Leukemia and in NHL B-Cell Lines. Acknowledgement: Special Thanks to Dr. Rassenti, Ph.D., CRC Tissue Core Director, for Providing CLL Samples. ASH Abstract 2003

31. Jane N. Winter, Edie Weller, Sandra J. Horning, Maryla Krajewska, Daina Variakojis, Thomas M. Habermann, Richard I. Fisher, Paul J. Kurtin, William R. Macon, Mukesh Chhanabhai, Raymond E. Felgar, Eric Hsi, L.J. Medeiros, James K. Weick, John Reed, Randy D. Gascoyne. Rituximab (R) Alters the Prognostic Indicator Profile in Diffuse Aggressive Non-Hodgkin Lymphomas. ASH Abstract 2003

32. Lin CW, Manshouri T, Jilani I, Neuberg D, Patel K, Kantarjian H, Andreeff M, Estrov Z, Beran M, Keating M, Estey E, Albitar M. Proliferation and apoptosis in acute and chronic leukemias and myelodysplastic syndrome. Leuk Res. 2002 Jun;26(6):551-9.

33. Battle TE, Frank DA. STAT1 mediates differentiation of chronic lymphocytic leukemia cells in response to Bryostatin 1. Blood. 2003;102:3016-24

34. Battle TE, Castro-Malaspino H, Gribben JG and Frank DA. Sustained complete remission of CLL associated with use of a Chinese herbal extract: case report and mechanistic analysis. Leuk Res. 2003;27:859-63.

35. Gricks C and Gribben JG "Cytotoxic T cell responses against immunoglobulin in malignant and normal B cells: Implications for tumor immunity and autoimmunity" Current Pharmaceutical Design 2003; 9:1889-903.

36. Gricks C, Zahrieh D, Zauls AJ, Drandi D, Gorgun G, Mauerer K, Neuberg D and Gribben JG. Differential regulation of gene expression following CD40 activation of healthy compared to leukemic B cells. Blood. In press

37. Harig S, Witzens M, Krackhardt AM, Trojan A, Barrett P, Brodrick R, Zauls AJ, Gribben JG. Induction of cytotoxic T-cell responses against immunoglobulin V region-derived peptides modified at human leukocyte antigen-A2 binding residues. Blood 2001 98 :2999-3005

38. Krackhardt AM, Harig S, Witzens M, Broderick R, Barrett P, Gribben JG. T-cell responses against chronic lymphocytic leukemia cells: implications for immunotherapy. Blood 2002 100:167-173

39. Trojan A, Schultze JL, Witzens M, Volderheide RH, Ladetto M, Donovan JW, Gribben JG. Immunoglobulin framework-derived peptides function as cytotoxic T cell epitopes commonly expressed in B cell malignancies Nature Medicine, 2000, 6: 667-672.

40. Krackhardt AM, Witzens M, Harig S, Hodi FS, Zauls AJ, Chessia M, Barret P, Gribben JG. Identification of tumor-associated antigens in chronic lymphocytic leukemia by SEREX. Blood 2002 100:2123-2131

41. Battle TE, Wierda WG, Rassenti LZ, Zahrieh D, Neuberg D, Kipps TJ, Frank DA. In vivo activation of STAT1 following CD154 gene therapy for chronic lymphocytic leukemia is associated with clinical and immunologic response. Clinical Cancer Research 2003 9(6):2166-72.

42. Gullu Gorgun, David Zahrieh, Daniela Drandi, Donna Neuberg, John Gribben. Gene Expression Profiling Reveals Defects in Genes Regulating T Cell Diffentiation and Effector Pathways in T Cells in Patients with CLL. ASH Abstract 2003

43. Katja Mauerer, Gullu Gorgun, Daniela Drandi, John G. Gribben. Impact of Binding Affinity to HLA*A0201 on Both Generation of Cytotoxic T Cells and Their Effector Function To Kill Peptide Pulsed APCs and CLL Cells. ASH Abstract 2003

44. Daniela Drandi, Charles Lee, Paola Dal Cin, John G. Gribben. Array-Based Comparative Genomic Hybridization Identifies Deletion at 14q32 as a New Prognostic Marker in Chronic Lymphocytic Leukemia (CLL). ASH Abstract 2003

45. Aihong Li, Scott Armstrong, Montse Rue, Hongjun Wang, Jianbiao Zhou, Lewis B. Silverman, Stephen E. Sallan, John G. Gribben. VH Gene Usage, Incomplete DJH Recombinations and MLL Rearrangements in Infant with B-Lineage Acute Lymphoblastic Leukemia: Implications for Leukemic Transformation Occurring at an Earlier Stage of B Cell Development. ASH Abstract 2003

46. Bradley T. Messmer, Davorka Messmer, Steven L. Allen, Kanti R. Rai, Marc Hellerstein, Nicholas Chiorazzi. Greater In Vivo B-CLL Cell Turnover Is Associated with Progressive Peripheral Leukemic Burden. ASH Abstract 2003

47. Rajendra N. Damle, Julia Tai, Martin Lesser, Prasad R. Kudalkar, Tarun Wasil, Bradley T. Messmer, Steven L. Allen, Kanti R. Rai, Nicholas Chiorazzi. In-Depth Analysis of Telomere Length Reveals Intraclonal Heterogeneity of Circulating B-CLL Cells. ASH Abstract 2003

48. Davorka Messmer, Gloria Telusma, Emilia Albesiano, Steven Allen, Kanti Rai, Nicholas Chiorazzi. Dendritic Cells Generated from CLL Patients Are Phenotypically and Functionally Normal and Induce an In Vitro Recall Response to Autologous T Cells from Vaccinated Patients. ASH Abstract 2003

49. Kanti R. Rai, Nancy Driscoll, Dale Janson, Alyssa Echevarria, Manish Sheth, Archana Bhargava, Simon Vinarsky, Uzma Iqbal, Tarun Wasil, Bhoomi Mehrotra. Incidence of CLL and Other Cancers in Families of CLL Patients. ASH Abstract 2003

50. Gandhi, V., Plunkett, W., Weller, S., Du, M., Ayres, M., Rodriguez, Jr., C.O., Ramakrishna, P., Hodge, J.P., Keating, M.J. Evaluation of the Combination of Nelarabine and Fludarabine in Leukemias: Clinical Response, Pharmacokinetics and Pharmacodynamics in Leukemia Cells, J. Clin. Oncol., 19:2142-2132,2001.

51. Gandhi, V. and Plunkett W. Combination strategies for purine nucleoside analogs, in “The Chronic Lymphoid Leukemias”, Cheson, B. D., ed., Marcel Dekker, Inc., NY., pp. 195-208, 2001.

52. Gandhi V. and Plunkett, W. Cellular and clinical pharmacology of fludarabine. Clinical Pharmacokinetics, 41:93-103, 2002.

53. Kantarjian, H. Gandhi, V., Kozuch, P., Faderl, S., Giles, F., Cortes, J., O’Brien, S., Ibrahim, N., Khuri, F., Du M., Rios,M.B., Plunkett, W., and Keating M.J. Phase I Clinical And Pharmacology Study Of Clofarabine (Cl-F-ara-A; 2 Chloro-2’-Fluoro-Deoxy-9-beta-D-Arabinofuranosyladenine) in Patients with Solid and Hematologic Cancers, J Clin. Oncol, 21:1167-1173, 2003.

54. Huang, P., Feng, L., Oldham, E. A., Keating, M. J., and Plunkett, W. Superoxide dismutase: a novel target for selective killing of cancer cells. Nature, 407:390-395, 2000

55. Huang, P., Sandoval, A., van den Neste, E., Keating, M.J., and Plunkett, W. Inhibition of RNA transcription: a biochemical mechanism of action against chronic lymphocytic leukemia cells by fludarabine. Leukemia, 8:1405-1413, 2000

56. Hileman EO, Achanta G, and Huang P. Superoxide dismutase: an emerging chemotherapeutic target. Expert Opinion on Therapeutic Targets 5:697-710, 2001.

57. Carew, J.S., Zhou, Y., Albitar, M., Keating, M.J., Huang, P. Mitochondrial DNA Mutations in Primary Leukemia Cells after Chemotherapy: Clinical Significance and Therapeutic Implications. Leukemia, 17:1437-1447, 2003.

58. Pelicano, H., Zhou, Y., Hileman, E. O., Feng, L., Plunkett, W. Keating, M. J., and Huang, P. Interfering of the mitochondrial electron transport: A novel strategy to enhance drug-induced apoptosis in leukemia cells through a free radical-mediated mechanism, J. Biol Chem, 278:37832-37839, 2003

59. Zhou, Y., Hileman, E. O., Plunkett, W., Keating, M. J., and Huang, P. Free radical stress in chronic lymphocytic leukemia cells and its role in cellular sensitivity to ROS-generating anticancer agents. Blood, 101:4098-4104, 2003.

60. Yamauchi, T., Nowak, B., Keating, M.J., and Plunkett, W. DNA repair initiated in chronic lymphocytic leukemia lymphocytes by 4-hydroperoxycyclophosphamide is inhibited by fludarabine and clofarabine. Clin. Cancer Res.,7:3580-3589, 2001.

61. Yamauchi, T., Keating, M.J., and Plunkett, W. UCN-01 (7-hydroxystaurosporine) inhibits DNA repair and increases cytotoxicity in normal lymphocytes and CLL lymphocytes. Molecular Cancer Therap., 1:287-294, 2002.

62. Rao, V.A. and Plunkett, W. Activation of p53-mediated apoptotic pathway in quiescent lymphocytes after inhibition of DNA repair by fludarabine. Clin. Cancer Res., 9:3204-3212, 2003.

63. Susan M. O’Brien, John G. Gribben, Deborah A. Thomas, Maher Albitar, William Wierda, Alessandra Ferrajoli, Susan Lerner, Hagop M. Kantarjian, Thomas Kipps, Michael J. Keating, the CLL Research Consortium. Alemtuzumab for Minimal Residual Disease in CLL. ASH Abstract 2003

64. Thomas J. Kipps, Januario E. Castro, William Wierda, Michael J. Keating, Jan Bole, Jayne Meyer, Heather Roehrs, Lisa Bouchard, Vivian Yuan, Harjinder Chana, Lisa Hami, Mark Bonyhadi, Ronald J. Berenson, Mark W. Frohlich. A Phase I/II Trial of Xcellerated T Cells in Patients with Chronic Lymphocytic Leukemia (CLL). ASH Abstract 2003

65. Iman Jilani, Susan O’Brien, Hagop Kantarjian, Jitkaroon Caiyo, Francis Giles, Alessandra Ferrajoli, Michael Keating, Maher Albitar. Quantitative Measurement of CD52 on the Surface of CLL Cells before and after Treatment with Almetuzumab. ASH Abstract 2003

66. Iman Jilani, Susan O’Brien, Hagop Kantarjian, Jitkaroon Caiyo, Francis Giles, Alessandra Ferrajoli, Michael Keating, Maher Albitar. CD23 Quantification in Chronic Lymphocytic Leukemia and the Effects of Anti-CD23 Therapy on Its Levels. ASH Abstract 2003

67. Maher Albitar, Kim-Anh Do, Marcella M Johnson, Francis J Giles, Iman Jilani1, Susan O’Brien, Jorge Cortes, Deborah Thomas, Laura Z. Rassenti, Thomas J Kipps, Hagop M Kantarjian, Michael Keating.Free circulating sCD52 as a tumor marker in chronic lymphocytic leukemia and its implication on therapy with anti-CD52 antibodies. 2003 123(5) :850-7.

68. Neil E. Kay, Thomas Lin, Timothy Call, Diane F. Jelinek, Nancy D. Bone, Gordon W. Dewald, Nyla A. Heerema, Renee Tschumper, Lisa Smith, Susan M. Geyer, John C. Byrd. Pentostatin Combination Therapy for Untreated B-Chronic Lymphocytic Leukemia. Session Type: Poster Session 675-II ASH 2003

69. Lucas DM, Davis ME, Parthun MR, Mone AP, Kitada S, Cunningham KD, Flax EL, Wickham J, Reed JC, Byrd JC, Grever MR. The histone deacetylase inhibitor MS-275 induces caspase-dependent apoptosis in B-cell chronic lymphocytic leukemia cells. Leukemia. 2004 Apr 29 [Epub ahead of print]

70. Rush LJ, Raval A, Funchain P, Johnson AJ, Smith L, Lucas DM, Bembea M, Liu TH, Heerema NA, Rassenti L, Liyanarachchi S, Davuluri R, Byrd JC, Plass C. Epigenetic profiling in chronic lymphocytic leukemia reveals novel methylation targets. Cancer Res. 2004 Apr 1;64(7):2424-33.

71. Byrd JC, Kitada S, Flinn IW, Aron JL, Pearson M, Lucas D, Reed JC. The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction. Blood 2002 Vol 99 Number 3

72. Aron Jl, Parthun MR, Marcucci G, Kitada S, Mone AP, Davis ME, Shen T, Murphy T, Wickham J, Kanakry C, Lucas DM, Reed JC, Grever MR, Bryd JC, Depsipeptide (FR901228) induces histone acetylation and inhibition of histone deacetylase in chronic lymphocytic leukemia cells concurrent with activation of caspase 8-mediated apoptosis and down-regulation of c-Flip protein. Blood 2003 102: 652-658

73. Rosenwald A, Alizadeh AA, Widhopf G, Simon R, Davis RE, Yu X, Yang L, Pickeral OK, Rassenti LZ, Powell J, Botstein D, Byrd JC, Grever MR, Cheson BD, Chiorazzi N, Wilson WH, Kipps TJ, Brown PO, Staudt LM. Relation of Gene Expression Pheno- type to Immunoglobulin Mutation Genotype in B Cell Chronic Lymphocytic Leukemia. Journal of Experimental Medicine December 2001 1639-1647

74. John C. Byrd, Susan O’Brien, Ian Flinn, Thomas J. Kipps, Mark A. Weiss, Jennifer Reid, Dee Wynne, Bryan R. Leigh. Interim Results from a Phase I Study of Lumiliximab (IDEC-152, Anti-CD23 Antibody) Therapy for Relapsed or Refractory CLL. ASH Abstract 2003

75. Stephanie R. Brockman, Tait D. Shanafelt, Sarah F. Paternoster, Danielle M. Nast, Heather C. Flynn, Nancy D. Bone, Susan M. Geyer, Carlo M. Croce, Robert L. Phyliky, Thomas E. Witzig, Neil E. Kay, Gordon W. Dewald. Chromosome anomalies detected by interphase fluorescence in situ hybridization: correlation with significant biological features of B-cell chronic lymphocytic leukaemia.Br J Haematol. 2003 Apr;121(2):287-95.

76. John C. Byrd, Kanti R. Rai, Bercedis L. Peterson, Frederick R. Appelbaum, Vicki A. Morrison, Jonathan E. Kolitz, Lois Shepherd, John D. Hines, Charles A. Schiffer, Richard A. Larson. The Addition of Rituximab to Fludarabine Significantly Improves Progression-Free and Overall Survival in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Patients. ASH Abstract 2003

77. Byrd JC, Rai KR, Sausville EA, Grever MR. New and Old Treatments of Chronic Lymphocytic Leukemia: It’s Time for a Treatment Reassessment. Sem Oncol. 25:65-73, 1998.

78. Byrd JC, Grever MR, Waselenko JK, Willis CR, Park KP, Goodrich A, Lucas MA, Shinn CA, Flinn IW. Theophylline, Pentostatin (Nipent), and Chlorambucil: A Does Escalation Study Targeting Intrinsic Biologic Resistance Mechanisma in Patients with Relapsed Lymphoproliferative Disorders. Semin Oncol. 27:44-51, 2000.

79. Byrd JC, Waselenko JK, Rai KR, Keating MJ, Grever MR. Novel Therapies for Chronic Lymphocytic Leukemia in the 21st Century. Semin Oncol. 27(5):581-597, 2000.

80. Reed JC, Kitada S, Kim Y, Byrd JC. Modulating Apoptosis Pathways in Low-Grade B-Cell Malignancies Using Biological Response Modifiers. Semin Oncol. 29:10-24, 2002.

81. Johnson AJ, Mone AP, Abhyanker V, Byrd JC. Advances in the Therapy of CLL. Curr Opin Hematol. 10:297-305, 2003

82. Lin TS, Lucas MS, Byrd JC. Rituximab Therapy for CLL. Semin Oncol Semin Oncol. 30:483-92, 2003

83. Byrd JC, Murphy T, Lucas MS, Haward R, Goodrich A, Park K, Pearson M, Buj V, Waselenko JK, Grever MR, and Flinn IW. Thrice Weekly Rituximab Demonstrates Significant Activity in Chronic Lymphocytic Leukemia. Blood. 96: 837a 2000.

84. Kitada S, Pearson M, Flinn IW, Shinn C, Reed JC, Byrd JC. The Mechanism of in vivo Leukemia Cell Clearance by Rituximab in Patients with CLL Involves Apoptosis by a Caspase 9 Pathway. Blood. 96: 515a 2000.

85. Pearson M, Buj, Shinn C, Waymer SF, Sickler J, Flynn JM, Lucas MS, Flinn IW, Byrd JC. GM-CSF Treatment Does not Up-Regulate Expression of CD20 in vivo in Patients with Chronic Lymphocytic Leukemia. Blood. 96:166a 2000.

86. Maghraby E, Murphy T, Parthun M, Klisovic M, Sklenar A, Archer K, Whitman S, Grever M, Byrd JC, Marcucci G. Depsipeptide (FR901228) Induces Lysine-Specific Histone Acetylation, Differentiation and Apoptosis is Acute Myeloid Leukemia Cells and Demonstrates Synergy with Decitabine. Blood. 98:11 103a, 2001.

87. Lucas M, Flinn IW, Goodrich AL, Murphy T, Park K, Grever MR, Lehman T, Byrd JC. TNF-a and TNF-b Promotor Polymorphisms May Relate to Response to Rituximab Therapy. Blood. 98:11 634a, 2001.

88. Byrd JC, Peterson BL, Park K, Morrison VL, Vardiman JW, Jacobson R, Rai K, Larson RA. Concurrent Rituxumab and Fludarabine has a Higher Complete Response Rate Than Sequential Treatment in Untreated Chronic Lymphocytic Leukemia (CLL) Patients: Results From CALGB 9712. Blood. 98:11 772a, 2001.

89. Aron J, Murphy T, Parthun MR, Bannerji R, Kanakry C, Lucas D, Flinn IW, Marcucci G, Grever MR, Byrd JC. The Histone Deacetylase Inhibitor Depsipeptide (FR901228) Induces Apoptosis Via Activation of the Caspase 8 Pathway Concurrent with Lysine Specific Acetylation in Chronic Lymphocytic Leukemia Cells. Blood. 98:11 807a, 2001.

90. Bannerji R, Kitada S, Flinn IW, Pearson M, Lucas D, Grever MR, Reed JC, Byrd JC. Campath-1H Antibody Induces Transmembrane Signaling in vitro and in vivo in Patients with Chronic Lymphocytic Leukemia (CLL) and Promotes Tumor Clearance in Part Through Caspase mediated Apoptosis. Blood. 98:11 808a, 2001.

91. Link BK, Wang H, Byrd JC, Leonard JP, Davis TA, Flinn I, Hall WC, Turner JF, Bowles J, Shannon M, Levitt D, Weiner GJ. Prolonged Clinical Responses in Patients with Follicular Lymphoma Treated on a Phase I Trial of the Anti-HLA-DR Monoclonal Antibody Remitogen (Hu1D10). Blood. 98:11 244b, 2001.

92. Baird ME, Lucas DM, Mone AP, Waymer S, Warrell RP, Byrd JC, Grever MR. G3139 Promotes Release of IL-8 by Chronic Lymphocytic Leukemia Cells Cultured in vitro: Potential Implications for Therapeutic Use. Blood. 98:11 281b, 2001.

93. Lucas DM, Baird ME, Neuberg DS, Tallman MS, Flinn IW, Byrd JC, Grever MR. Importance of Culture Conditions for in vitro Chemosensitivity Assessment in Chronic Lymphocytic Leukemia Cells: Preliminary Results From Laboratory Studies, Eastern Cooperative Oncology Group Study 2997. Blood. 98:11 284b, 2001.

94. Byrd JC, Peterson B, Park K, Morrison V, Vardiman JW, Jacobson RJ, Rai K, Larson AR. Rituximab Added to Fludarabine Improves Response in Previously Untreated Chronic Lymphocytic Leukemia: Preliminary Results From CALGB 9712. American Society of Clinical Oncology. 20:280a 1116, 2001.

95. Link BK, Wang H, Byrd JC, Leonard JP, Davis TA, Flinn I, Hall WC, Turner JF, Levitt D, Weiner GJ. Phase I Study of Hu1D10 Monoclonal Antibody in Patients with B-Cell Lymphoma. American Society of Clinical Oncology. 20:284a 1135,2001.

96. Lucas DM, Parthun MR, Mojica RD, Mone AP, Byrd JC, Grever MR. MS-275 Reduces Viability and Induces Changes in Histone Acetylaton in Cells From Patients with B-Cell Chronic Lymphocytic Leukemia (B-CLL). American Association for Cancer Research. 93rd Annual Meeting Program, 2002.

97. Bruner RJ, Marcucci G, Binkley P, Fischer B, Parthun M, Davis M, Xiao J, Chan K, Wright J, Grever MR, Byrd JC. A Phase I Study to Determine Minimal Effective Pharmacologic Dose of Depsipeptide (FR901228) in Selected Hematologic Malignancies. Program/Proceedings American Society of Clinical Oncology. 21: 265a 1059, 2002.

98. Abhyankar VV, Lucas MS, Stock W, Aron JL, Briggs BR, Mone A, Porcu P, Wang H, Chen H, Flinn IW, Grever MR, Byrd JC. Phase I Study of Escalated Thrice Weekly Dosing of Hu1D10 in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Minimal Toxicity and Early Observation of in vivo Tumor Cell Apoptosis. Program/Proceedings American Society of Clinical Oncology. 21:268a 1069, 2002.

99. Smith LL, Heerema N, Hackbarth ML, Flinn IW, Young D, Proffitt JH, Byrd JC. Interphase Cytogenetics Are Predictive of Chronic Lymphocytic Leukemia (CLL) Response to Thrice Weekly Rituximab Therapy. Blood 100(11 part 1) abstract 2147, p546, 2002.

100. Bruner RJ, Marcucci G, Binkley P, Xiao J, Chan K, Parthun M, Davis M, Fischer B, Shank F, Moran M, Grever MR, Byrd JC. Phase I Trial of the Histone Deacetylase Inhibitor Depsipeptide (FR901228) in Fludarabine Refractory Chronic Lymphocytic Leukemia. Blood 100(11 part 1) abstract 1492, p86a., 2002

101. Lucas DM, Davis M, Parthun MR, Mojica RC, Mone AP, Zwiesler J, Byrd JC, Grever MR. MS-275 Promotes Apoptosis in Cells from Patients with B-Cell Chronic Lymphocytic Leukemia (B-CLL) Concurrent with Inhibition of Histone Deactylase. Blood 100 (11 part 1) abstract 1500, p386a., 2002

102. Rai KR, Byrd JC, Peterson B, Larson RA. A Phase II Trial of Fludarabiine Followed by Alemtuzumab (Campath-1H) in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Patients with Active Disease: Cancer and Leukemia Group B (CALGB) Study 19901 Blood 100(11 part 1) abstract 772, p205a., 2002.

103. Kitada S, Young D, Pearson M, Flinn IW, Shinn CA, Reed JC, Byrd JC. Mcl-1/Bax Ratio Is a Predictor for Outcome of Rituximab Therapy in Patients with CLL. Blood 100(11 part 1) abstract 1466, p376a., 2002

104. Dewald GW, Paietta E, Goloubeva O, Bennett JM, Brockman SR, Paternoster SF, Lucas D, Neuberg D, Flinn I, Tallman M, Grever MR, Byrd JC. Correlation of Interphase Fluorescence In Situ Hybridization (FISH) Abnomalies with Cell Morphology and Immunophenotyping in Chronic Lymphocytic Leukemia (B-CLL). Blood 100(11 part 1) abstract 2334, p594a, 2002

105. Lin TS, Stock W, Lucas MS, Porcu P, Abhyankar VV, Jefferson SK, Briggs B, Wang H, Cheney C, Flinn IW, Grever MR, Dalton JT, Byrd JC. A Phase I Dose Escalation Study of Apolizumab (Hu1D10) Using a Stepped Up Dosing Schedule in Patients with Chronic Lymphocytic Leukemia (CLL) and Acute Lymphocytic Leukemia (ALL). Blood 100 (11 part 1) abstract 3167, p 807a,2002

106. Lucas DM, Baird ME, Byrd JC, Tschumper RC, Jelinek DF, Kitada S, Reed JC, Rosenwald A, Staudt LM, Neuberg DS, Tallman MS, Flinn IW, Grever MR. ZAP70 and Caspase-3 Protein Expression Independently Associate with Immunoglobulin VH Gene Mutational Status in Patients with B-Cell Chronic Lymphocytic Leukemia (B-CLL). Blood 100(11 part 1) abstract 1478, p381a, 2002

107. Raval A, Rush LJ, Funchain P, Flak E, Davis M, Johnson AJ, Byrd JC, Plass C. Aberrant DNA Methylation in Chronic Lymphocytic Leukemia: A Role in Pathogenesis? Blood 100 (11 part 1) abstract 1469, p379a, 2002

108. Mone AP, Lucas D Aron J, Cheney C, Johnson AJ, Bains SK, Tso JY, Weiner G, Green J, Grever MR, Byrd JC. Hu1D10 with P13 Kinase Inhibitors. Blood 100(11 part 1) abstract 1496, p 386a, 2002

109. Farag SS, Flinn IW, Lehman T, Modali R, Byrd JC. FcRIIIa and FcRIIa Polymorphisms Do Not Predict Response to Rituximab in B-Cell Chronic Lymphocytic Leukemia. Blood 102, No. 11, abstract 2501, p. 675a, 2003

110. Johnson AJ, Eisenbeis CF, Cheney CM, Mone AP, Lucas DM, Byrd JC. Rituximab and 17-AAG Synergistically Induce Apoptosis in B-Cell Chronic Lymphocytic Leukemia (CLL). Blood 102, No. 11, abstract 1594, p.437a, 2003

111. Kay NE, Lin T, Call T, Jelinek DF, Bone ND, Dewald GW, Heerema NA, Tschumper R, Smith L, Geyer SM, Byrd JC. Pentostatin Combination Therapy for Untreated B-Chronic Lymphocytic Leukemia. Blood 102, No. 11, abstract 2504, p.676a, 2003

112. Rai KR, Byrd JC, Peterson B, Gautier M, Larson RA. Subcutaneous Alemtuzumab Following Fludarbine for Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL): CALGB Study 19901 Blood 102, No. 11, abstract 2506, p.676a, 2003

113. Mone AP, Cheney CM, Lin TS, Jefferson S, Byrd JC. Campath-1H Induces Caspase-Independent Apoptosis in Primary Human Chronic Lymphocytic Leukemia Cells through a Cytoskeletal Dependent Mechanism. Blood 102, No. 11, abstract 1588. p.436a, 2003

114. Mone, AP, Cheney C, Huang P, Pelicano H, Green J, Tso JY, Johnson A, Byrd JC. Hu1D10 Activates Both Death and Survival Pathways in Primary Human Chronic Lymphocytic Leukemia Cells: Hu1D10 Induced Reactive Oxygen Species Activate the AKT Survival Pathway. Blood 102, No. 11, abstract 1595, p.438a, 2003

115. Lucas DM, Zhang L, Freitas MA, Wickham J, Parthun MR, Davis ME, Marcucci G, Byrd JC, Grever MR. MS-275 Mediated Apoptosis and Generation of Reactive Oxygen Species Are Caspase Dependent in B-Cell Chronic Lymphocytic Leukemia (CLL). Blood 102, No. 11, abstract 1566, p.431a, 2003

116. Rassenti LZ, Toy TL, Huynh L, Greaves A, Gribben JG, Keating MJ, Rai KR, Flinn IW, Byrd JC, Kay NE, Goldin LR, Caporaso NE, Kipps TJ. High Similarity between Familial and Sporadic Cases of Chronic Lymphocytic Leukemia. Blood 102, No. 11, abstract 670a, 2003.

117. Kasamon YL, Byrd JC, Grever MR, Diehl LF, Lucas MS, Garrett ES, Flinn IW. IL-2 Does Not Protect Against Fludarabine and Cyclophosphamide Induced Immunosuppression. Blood 102, No. 11, abstract 2350, p.637a, 2003

118. Grever MR, Dewald GW, Lucas DM, Neuberg DS, Baird ME, Paternoster SF, Brockman SR, Lozanski G, Rizouli V, Gribben JG, Flinn IW, Tallman MS, Kitada, Reed JC, Staudt LM, Paietta E, Byrd JC. ZAP-70 Protein Expression Varies by Interphase Cytogenetic Group and May Predict Disease Progression to Requirement of Treatment among Select Genetic Groups in Patients with Chronic Lymphocytic Leukemia (CLL). Blood 102, No. 11, abstract 244, p.73a, 2003

119. Byrd JC, Brien SO, Flinn I, Kipps TJ, Weiss MA, Reid J, Wynne D, Leigh BR. Interim Results from a Phase I Study of Lumiliximab (IDEC-152, Anti-CD23 Antibody) Therapy for Relapsed or Refractory CLL. Blood 102, No. 11, abstract 248, p.74a, 2003

120. Rassenti LZ, Huynh L, Toy TL, Gribben JG, Keating MJ, Rai, Flinn IW, Byrd JC, Kay NE, Greaves A, Weiss A, Kipps TJ. ZAP-70 Is a More Reliable Marker of Disease Progression Risk Than Immunoglobulin Mutation Status in Chronic Lymphocytic Leukemia. Blood 102, No. 11, abstract 106, p.34a, 2003

121. Michael R. Grever, Gordon W. Dewald, David M. Lucas, Donna S. Neuberg, Maureen E. Baird, Sarah F. Paternoster, Stephanie R. Brockman, Gerard Lozanski, Vassiliki Rizouli, John G. Gribben, Ian W. Flinn, Martin S. Tallman, Shinichi Kitada, John C. Reed, Louis M. Staudt, Elisabeth Paietta, John C. Byrd. ZAP-70 Protein Expression Varies by Interphase Cytogenetic Group and May Predict Disease Progression to Requirement of Treatment among Select Genetic Groups in Patients with Chronic Lymphocytic Leukemia (CLL). ASH Abstract 2003

122. Calin GA, Dumitru CD, Shimizu M, Bichi R, Zupo S, Noch E, Alder H, Rattan S, Keating MJ, Rai KR, Rassenti L, Kipps TJ, Negrini M, Bullrich F, Croce CM. Frequent deletions and down regulation of micro RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. PNAS 2002 99: 15524-15529

123. Mabuchi H, Fujii H, Calin GA, Alder H, Negrini M, Rassenti L, Kipps TJ, Bullrich F, Croce CM. Cloning and characterization of CLLD6, CLLD7 and CLLD8, novel candidate genes for leukemogenesis and chromosome 13q14, a region commonly deleted in B cell chronic lymphocytic leukemia. Cancer Research 2001 61:2870-2877

124. Bullrich F, Fujii H, Calin GA, Mabuchi H, Negrini M, Pekarsky Y, Rassenti L, Alder H, Reed JC, Keating MJ, Kipps TJ, Croce CM. Characterization of the 13q14 tumor suppressor locus in CLL: Identification of ALT1 an alternative slpice variant of the LEU2 gene. Cancer Research 2001 61:6640-6648

125. Bichi R, Shinton SA, Martin ES, Koval A, Calin GA, Cesari R, Russo G, Hardy RR, Croce CM. Human chronic lymphocytic leukemia modeled in mouse by targeted TCL1 expression. PNAS, 2002, 99:6955

126. Hideshi Ishii, Yusuke Furukawa, Louise Y. Fong, Andrea Vecchione, Nicola Zanesi, Yutaka Furukawa, Krittaya Sutheesophon, Francesco Trapasso, Raffaele Baffa, Kay Huebner, Carlo M. Croce. A Link between Common Chromosome Fragile Site Genes and Tumorigenesis. ASH Abstract 2003

127. Hallas, C., Pekarsky, Y., Itoyama, T., Varnum, J., Bichi, R., Rothstein, J.L. and Croce, C.M.: Genomic analysis of human and mouse TCL1 loci reveals a complex of tightly clustered genes. Proc. Natl. Acad. Sci., USA, 96: 14418-14423, 1999.

128. Bullrich, F., Rasio, D., Kitada, S., Starostik, P., Kipps, T., Keating, M., Albitar, M., Reed, J.C. and Croce, C.M.: ATM mutations in B-cell chronic lymphocytic leukemia. Cancer Res., 59: 24-27, 1999.

129. Pekarsky, Y., Koval, A., Hallas, C., Bichi, R., Tresini, M., Malstrom, S., Russo, G., Tsichlis, P., Croce, C.M.: Tcl1 enhances Akt kinase activity and mediates it nuclear translocation. Proc. Natl. Acad. Sci., USA, 97: 3028-3033, 2000.

130. Narducci, M.G., Pescarmona, E., Lazzeri, C., Signoretti, S., Lavinia, A.M., Remotti, D., Scala, E., Baroni, C.D., Stoppacciaro, A., Croce. C.M. and Russo, G: Regulation of TCL1 expression in B- and T-cell lymphomas and reactive lymphoid tissues. Cancer Res., 60: 2095-2100, 2000.

131. Pekarsky, Y., Hallas, C., Palamarchuk, A., Koval, A., Bullrich, F., Bichi, R., and Croce, C.M.: Akt Phosphorylates and regulates the ophan nuclear receptor Nur77. Proc. Natl. Acad. Sci., USA, 98: 3690-3694, 2001.

132. Baldassarre, G., Fedele, M., Battista, S., Vecchione, A., Klein-Szanto, A.J.P., Santoro, M., Waldmann, T.A., Azimi, N., Croce, C.M. and Fusco, A.: Onset of natural killer cell lymphomas in transgenic mice carrying a truncated HMGI-C gene by the chronic stimulation of the IL-2 and IL-15 pathway. Proc. Natl. Acad. Sci., USA 98: 7970-7975, 2001.

133. Bullrich, F., and Croce, C.M.: Molecular biology of chronic lymphocytic leukemia. Chronic Lymphoid Leukemias, 2nd Ed., Marcel Dekker, Inc., Chpt. 2: 9-32, 2001.

134. Bullrich, F., Fujii, H., Calin, G., Mabuchi, H., Negrini, M., Pekarsky, Y., Rassenti, L., Alder, H., Reed, J.C., Keating, M.J., Kipps, T.J. and Croce, C.M.: Characterization of the 13q14 tumor supressor locus in CLL. Identification of ALT1, an alternative splice variant of the LEU2 gene. Cancer Res., 61: 6640-6648. 2001.

135. Pekarsky, Y., Hallas, C. and Croce, C.M.: Molecular Basis of Mature T Cell Leukemia. JAMA, 286: 2308-2314, 2001.

136. Pekarsky, Y., Hallas, C. and Croce, C.M.: The role of TCL1 in human T-cell leukemia. Oncogene 20: 5638-5643, 2001.

137. Petock, J.M., Torshin, I.Y., Wang, Y-F., DuBois, G.C., Croce, C.M., Harrison, R.W. and Weber, I.T.: Structure of murine Tcl1 at 2.5 A resolution and implications for the TCL oncogene family. Acta Cryst., 57: 1545-1551, 2001.

138. Calin, G.A., Trapasso, F., Shimizu, M., Godwin, A.K., Bernardi, G., Rattan, S., Alder, H., Baldassarre, G., Mabuchi, H., Baffa, R., Shiraishi, T., Hansen, L.L., Dighiero, G., Rassenti, L., Kipps, T., Movsas, B., Fusco, A., Mori, M., Russo, G., Bullrich, F., Negrini, M., and Croce, C.M.: Identification and characterization of ARLTS1, a candidate tumor suppressor gene on human chromosome 13q14. Cancer Cell, Submitted, 2004.

139. Narducci, M.G., Fiorenza, M.T., Kang, S-M., Bevilacqua, A., DiGiacomo, M., Remotti, D., Picchio, M.C., Fidanza, V., Cooper, M.D., Croce, C.M., Mangia, F., and Russo, G.: TCL1 participates in early embryonic development and is overexpressed in human seminomas. Proc. Natl. Acad. Sci., USA, 99: 11712-11717, 2002.

140. Cesari, R., Martin, E.S., Calin, G.A., Pentimalli, F., Bichi, R., McAdams, H., Trapasso, F., Drusco, A., Shimizu, M., Masciullo, V., d’Andrilli, G., Scambia, G., Picchio, M.C., Alder, H., Godwin, A.K., and Croce, C.M.: Parkin, a gene implicated in autosomal recessive juvenile Parkinsonism, is a candidate tumor suppressor gene on chromosome 6q25-27. Proc. Natl. Acad. Sci., USA, 100: 5956-5961, 2003.

141. Martin, E.S., Cesari, R., Pentimalli, F., Himelstein, A.L., Godwin, A.K., Negrini, M., and Croce, C.M.: The BCSC-1 locus at chromosome 11q23-q24 is a candidate tumor suppressor gene. Proc. Natl. Acad. Sci., USA, 100: 11517-11522, 2003.

142. Battista, S., Pentimalli, F., Baldassarre, G., Fedele, M., Fidanza, V., Croce, C.M., and Fusco, A.: Loss of hmga1 gene function affects embryonic stem cell lymphohemato-poietic differentiation. FASEB Jour., 17: 1496-1498, 2003.

143. Calin, G., Sevignani, C., Dmutru, C.D., Hyslop, T., Noch, E., Yendamuri, S., Shimizu, M., Rattan, S., Bullrich, F., Negrini, M., and Croce, C.M.: Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc. Natl. Acad. Sci., 101: 2999-3004, 2004.

144. Liu, C.-G., Calin, Meloon, B., Gamliel, N., Sevignani, C., Ferracin, M., Dumitru, C.D., Shimizu, M., Zupo, S., Dono, M., Alder, H., Bullrich, F., Negrini, M., and Croce, C.M.: An oligonucleotide microchip for genome-wide miRNA profiling of human and mouse tissues. Proc. Natl. Acad. Sci., USA, 2004, in press.

145. Calin, G.A., Liu, C.-G., Sevignani, C., Ferracin, M., Felli, N., Dumitru, C.D., Shimizu, M., Cimmino, A., Zupo, S., Dono, M., Del’Aquila, M.L., Rassenti, L., Kipps, T.J., Bullrich, F., Negrini, M., and Croce, C.M.: MicroRNA profiling reveals distinct signatures in B-cell chronic lymphocytic leukemia. Science, Submitted, April, 2004.

146. Payne PR, Johnson SB, et.al. Breaking The Translational Barriers: The Value Of Developing A Common Informatics Approach To Translational Research (Manuscript under Development for IOM, pending submission)

147. Starren JB, Payne PR. Quantifying Visual Similarity in Clinical Iconic Graphics AMIA Proceedings 2003 (poster abstract)

148. Payne PR, Greaves AW, Kipps TJ. CRC Clinical Trials Management System (CTMS): An Integrated Information Management Solutions for Collaborative Clinical Research. AMIA Proceedings 2003 (poster abstract)

149. Greaves AW, Payne PR, Rassenti L, Kipps TJ. CRC Tissue Core Management System (TCMS): Integration of Basic Science and Clinical Data for Translational Research. AMIA Proceeding 2003 (poster abstract)

150. Payne PR, Starren JB. Modeling Categorical Sorting Behavior. Submitted to MedInfo 2004 (poster abstract)

151. Payne PR, Greaves AW. An Integrated Translational Research Information System Architecture. Submitted to MedInfo 2004 (poster abstract)

152. Keating MJ, Chiorazzi N, Messmer B, Damle RN, Allen SL, Rai KR, Ferrarini M, Kipps TJ. Biology and treatment of chronic lymphocytic leukemia. Hematology 2003: 153-175

153. Rieger R, Kipps TJ. CpG oligodeoxynucleotides enhance the capacity of adenovirus-medicated CD 154 gene transfer to generate effective B-cell lymphoma vaccines. Cancer Research July 15 2003 63(14): 4128-4135

154. Januario E. Castro, Shinichi Kitada, Anissa Agadir, John C. Reed, Thomas J. Kipps. G3139-Genasense Induces Apoptosis of Chronic Lymphocytic Leukemia Cells Via a Mechanism Dependent upon the Presence of Thymidine Nucleotides and Phosphorothioate Backbone and Not Antisense Bcl-2 Sequence. ASH Abstract 2003

155. Laura Z. Rassenti, Traci L. Toy, Lang Huynh, Andrew Greaves, John G. Gribben, Michael J. Keating, Kanti R. Rai, Ian W. Flinn, John C. Byrd, Neil E. Kay, Lynn R. Goldin, Neil E. Caporaso, Thomas J. Kipps. High Similarity between Familial and Sporadic Cases of Chronic Lymphocytic Leukemia. ASH Abstract 2003

156. Liguang Chen, John Apgar, Lang Huynh, Teresa Giago-Mcgahan, Laura Rassenti, Thomas J. Kipps. Expression of ZAP-70 Is Associated with Enhanced Phosphorylation of p72Syk, BLNK, and Phospholipase C Following B Cell Receptor Ligation in Chronic Lymphocytic Leukemia. ASH Abstract 2003

157. Roman Rieger, Mark J. Cantwell, Laura Z. Rassenti, Charles E. Prussak, Thomas J. Kipps. Cellular Immune Response to Ad-CD154 Immune Therapy for Chronic Lymphocytic Leukemia. ASH Abstract 2003

158. Mitsufumi Nishio, Frank Dicker, Laura Rassenti, Traci Toy, Howard B. Cottam, Dennis A. Carson, Michael Karin, Thomas J. Kipps. Chronic Lymphocytic Leukemia Cells That Express Unmutated Immunoglobulin Genes Are Uniquely Sensitive to Inhibitors of Kappa B Kinase-beta (IKK). ASH Abstract 2003

159. Frank S. Dicker, Laura Z. Rassenti, Thomas J. Kipps. Modulation of Cell Cycle-Regulated Genes Correlates with Late Sensitization to Fas-Mediated Apoptosis of CD40-Activated Chronic Lymphocytic Leukemia Cells. ASH Abstract 2003

160. Mitsufumi Nishio, Danelle F. James, Thomas J. Kipps. Different Activation of the NF-B Canonical and Alternative Pathway by Tumor Necrosis Factor (TNF) Family Proteins, BAFF and APRIL, in Chronic Lymphocytic Leukemia (CLL). ASH Abstract 2003

161. Frank S. Dicker, Laura Z. Rassenti, Thomas J. Kipps. CD40-Ligation Induces Latent Sensitivity to Death-Receptor-Mediated Apoptosis Via a p53-Independent Pathway in Chronic Lymphocytic Leukemia B Cells. ASH Abstract 2003

162. Liguang Chen, Lang Huynh, Frank Dicker, John Apgar, Teresa Giago-McGahan, Arthur Weiss, Thomas J. Kipps. Demonstration That ZAP-70 Directly Contributes to Enhanced B Cell Receptor Signaling in Chronic Lymphocytic Leukemia. ASH Abstract 2003

163. Laura Z. Rassenti, Lang Huynh, Traci L. Toy, John G. Gribben, Michael J. Keating, Kanti R. Rai, Ian W. Flinn, John C. Byrd, Neil E. Kay, Andrew Greaves, Arthur Weiss, Thomas J. Kipps. Zap-70 Is a More Reliable Marker of Disease Progression Risk Than Immunoglobulin Mutation Status in Chronic Lymphocytic Leukemia. ASH Abstract 2003

164. Rosewald A, Alizadeh AA, Widhopf G, Simon R, Davis RE, Yu X, Yang, Pickeral OK, Rassenti LZ, Powell J , Botstein D, Byrd JC, Grever MR, Cheson BD, Chiorazz N, Wilson WH, Kipps TJ, Brown PO, Staudt LM. Relation of Gene Expression Phenotype to Immunoglobulin Mutation Genotyp in B Cell Chronic Lyphocytic Leukemia. Journal of Experimental Medicine December 2001 1639-1647

165. Hua XH, Genini D, Gussio R, Tawatao R, Shih H, Kipps TJ, Carson DA, Leoni LM. Biochemical genetic analysis of indanocine resistance in human leukemia. Cancer Research 2001 61:7248-7254

166. Genini D, Adachi S, Chao Q, Rose DW, Carrera CJ, Cottam HB, Carson DA, Leoni LM. Deoxyadenosine analogs induce programmed cell death in chronic lymphocytic leukemia cells by damaging the DNA and by directly affecting the mitochondria. Blood 2000 96:3537-3543

167. Genini D, Budihardjo I, Plunkett W, Wang X, Carrera CJ, Cottam HB, Carson DA, Leoni LM. Nucleotide requirements for the in vitro activation of the apoptosis protein-activating factior-1-mediated caspase pathway. JBC 2000 275:29-34

168. Xia C, Lee J, Wu CCN, Barchechath SD, Niemeyer C, Cottam HB, Leoni LM, Carson DA. A small molecule antagonizes IL-4/IL-13 mediated cell survival in leukemia and lymphoma cells In preparation, 2003

169. Wu CCN, Castro JE, Motta M, Cottam HB, Kyburz D, Kipps TJ, Corr M, Carson DA. Selection of oligonucleotide aptamers with enhanced uptake and activation of human leukemia B cells. In press in Human Gene Therapy 2003 14(9):849-60.

170. Desheng Lu, Yandong Zhao, Rommel Tawatao, Michael D. Rosenbach, Gilbert Weidinger, Randall T. Moon, Lorenzo M. Leoni, Maripat Corr, Dennis A. Carson Wnt Signaling in Chronic Lymphocytic Leukemia. ASH Abstract 2003

171. Desheng Lu, Yandong Zhao, Rommel Tawatao, Michael D. Rosenbach, Gilbert Weidinger, Randall T. Moon, Lorenzo M. Leoni, Maripat Corr, Dennis A. Carson Activation of the Wnt signaling pathway in Chronic lymphocytic leukemia. Proc Natl Acad Sci U S A. 2004 101(9):3118-23. Epub 2004.

172. Chen L, Widhopf G, Huynh L, Rassenti L, Rai KR, Weiss A, Kipps TJ. Expression of ZAP-70 is associated with increased B-Cell receptor signaling in chronic lymphocytic leukemia. Blood 2002 100:4609-4614

173. Chu P, Deforce D, Pedersen IM, Kim Y, Kitada S, Reed JC, Kipps TJ. Latent sensitivity to Fas-mediated apoptosis after CD40 ligation may explain activity of CD154 gene therapy in chronic lymphocytic leukemia. PNAS 2002 99:3852-3859

174. Tsukada N, Burger JA, Zvaifler NJ, Kipps TJ. Distinctive features of "nurselike" cells that differentiate in the context of chronic lymphocytic leukemia. Blood 2002 99:1030-1037